1. Hummel M, Marafioti T, Stein H. Immunoglobulin V genes in Reed-Sternberg cells. N Engl J Med 1996;334:405–6. [PubMed] 2. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte predominant Hodgkin's disease from a clonal expansion of highly mutated germinal center B cells. N Engl J Med 1997;337:453–8. [PubMed] 3. Izban KF, Nawrocki JF, Alkan S, et al. Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin's disease. Am J Clin Pathol 1998;110:599–606. [PubMed] 4. Braeuninger A, Hansmann M-L, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999;340:1239–47. [PubMed] 5. Küppers R, Klein U, Hansmann M-L, et al. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520–9. [PubMed] 6. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000;36:69–87. [PubMed] 7. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangement but defective immunoglobulin transcription. Blood 2000;95:1443–50. [PubMed] 8. Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene-rearrangements in Reed-Sternberg cells of classic Hodgkin's disease. Blood 2000;95:3020–4. [PubMed] 9. Jaffe ES. Introduction: Hodgkin's lymphoma—pathology, pathogenesis, and treatment. Semin Hematol 1999;36:217–19. [PubMed] 10. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol 1999;12:159–76. [PubMed] 11. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of tumor necrosis factor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1–14. [PubMed]
12. Kadin ME, Liebowitz DN. Cytokines and cytokine receptors in Hodgkin's disease. In: Mauch P, et al, eds. Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins, 1999:139.
13. Poppema S, Potters M, Emens R, et al. Immune reactions in classical Hodgkin's lymphoma. Semin Hematol 1999;36:253–9. [PubMed] 14. Ohshima K, Sugihara M, Suzumiya J, et al. Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Pathol Res Pract 1999;195:149–55. [PubMed] 15. Van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685–91. [PubMed] 16. Teofili L, Di Febo AL, Pierconti F, et al. Expression of c-met proto-oncogene and its ligand hepatocyte growth factor in Hodgkin's disease. Blood 2001;97:1063–9. [PubMed] 17. Harris NL, Jaffe ES, Stein H, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994;84:1361–92. [PubMed] 18. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–49. [PubMed] 19. Anagnostopolous I, Hansmann M-L, Fransilla K, et al. European task force on lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889–99. [PubMed] 20. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36:220–32. [PubMed] 21. Poppema S, Kaiserling E, Lennert K. Hodgkin's disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centers: a cytohistologic study. Histopathology 1979;3:295–308. [PubMed] 22. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease: a distinct clinicopathologic entity. Am J Surg Pathol 1994;18:526–30. [PubMed] 23. Rosenberg SA, Kaplan HS. Evidence of an orderly progression in the spread of Hodgkin's disease. Cancer Res 1966;26:1225–31. [PubMed] 24. Regula DP, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988;318:214–19. [PubMed] 25. Kim H. Composite lymphoma and related disorders. Am J Clin Pathol 1993;99:445–51. [PubMed] 26. von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin's disease: an immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin study group. Am J Pathol 1997;150:793–803. [PubMed] 27. Delabie J, Vanderberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992;16:37–48. [PubMed]
28. Lennert K. Malignant lymphomas other than Hodgkin's disease. New York: Springer-Verlag, 1978.
29. Nguyen PL, Ferry JA, Harris NL. Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease. A comparative immunohistochemical study. Am J Surg Pathol 1999;23:27–33. [PubMed] 30. Stein H, Marafioti T, Foss H-D, et al. Downregulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin's disease but not in lymphocyte predominant Hodgkin's disease correlates with immunoglobulin transcription. Blood 2001;97:496–501. [PubMed] 31. Laumen H, Nielsen PJ, Wirth T. The BOB.1/OBF.1 co-activator is essential for octamer-dependent transcription in B cells. Eur J Immunol 2000;30:458–69. [PubMed] 32. Munro J, Freedman A, Aster J, et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994;83:793–8. [PubMed] 33. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995;85:780–9. [PubMed] 34. Timmens W, Visser L, Poppema S. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab Invest 1986;54:457–61. [PubMed] 35. Hansmann M-L, Stein H, Dallenbach F, et al. Diffuse lymphocyte-predominant Hodgkin's disease (diffuse paragranuloma). A variant of the B-cell-derived nodular type. Am J Pathol 1991;138:29–36. [PubMed] 36. Kraus MD, Haley J. Lymphocyte predominance Hodgkin's disease. The use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 2000;24:1068–78. [PubMed] 37. Rudiger T, Ott G, Ott MM, et al. Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 1998;22:1184–91. [PubMed] 38. Delsol G, Brousset P, Chittal S, et al. Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamH1-W probes in Hodgkin's disease. Am J Pathol 1992;140:247–53. [PubMed] 39. Niedobiteck G, Young LS, Herbst H. Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. Cancer Surv 1997;30:143–62. [PubMed]
40. Diehl V, Josting A. Hodgkin's disease. Cancer J Sci Am 2000;6(suppl 2):S150–8.
41. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848–58. [PubMed]
42. Pileri S, Sabattini E, Tazzari PL, et al. Hodgkin's disease: update of findings. Haematology 1991;76:175–82.
43. Stein H, Herbst H, Anagnostopoulos I, et al. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol 1991;2:33–8.
44. Schwarting R, Gerdes J, Durkop H, et al. Ber-H2: a new anti-Ki-1 (CD-30) monoclonal antibody directed at a formol resistant epitope. Immunohistochemical and immunobiochemical characterization. Blood 1989;74:1678–89. [PubMed] 45. Durkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family which is characteristic for Hodgkin's disease. Cell 1992;68:421–7. [PubMed]
46. Nadali G, Vimante F, Chilosi M, et al. Soluble molecules as biological markers in Hodgkin's disease. Leuk Lymphoma 1997;26:99–105.
47. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992;i:1195–7.
48. Tazzari PL, Bolognesi A, De Totero D, et al. Ber-H2 (anti CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma. In vitro evaluation. Br J Haematol 1992;81:203–11. [PubMed] 49. Engert A, Gottstin C, Winkler U, et al. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. Leuk Lymphoma 1994;13:441–8. [PubMed] 50. Terenzi A, Bolognesi A, Pasqualucci L, et al. Anti-CD30 (Ber=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful activity against CD30+ tumour cells in vitro and in SCID mice. Br J Haematol 1996;92:872–9. [PubMed]
51. Millward C, Weidner N. CD30 (Ber-H2) expression in nonhematopoietic tumors. Applied Immunohistochemistry 1998;6:164–8.
52. Pileri SA, Roncador G, Ceccarelli C, et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol 1997;183:116–23. [PubMed] 53. Pileri SA, Poggi S, Sabattini E, et al. Is Hodgkin's disease a unique entity? Leuk Lymphoma 1995;15:3–6. [PubMed] 54. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the REAL classification. Ann Oncol 1997;8:583–92. [PubMed] 55. Falini B, Pileri S, Stein H, et al. Variable expression of leukocyte common antigen (CD45) in CD30 (Ki-1)-positive anaplastic large cell (ALC) lymphoma. Implication for the differential diagnosis between lymphoid and non-lymphoid malignancies. Hum Pathol 1990;21:624–9. [PubMed] 56. Korkolopoulou P, Cordell J, Jones M, et al. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease. Histopathology 1994;24:511–15. [PubMed]
57. Chang KL, Arber DA, Weiss LM. CD20: a review. Applied Immunohistochemistry 1996;4:1–15.
58. Filippa DA, Ladanyi M, Wollner N, et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood 1996;87:2905–17. [PubMed]
59. Chittal S, Al Saati T, Delsol G. Epithelial membrane antigen in hematolymphoid neoplasms. A review. Applied Immunohistochemistry 1997;5:203–15.
60. Watanabe K, Yamashita Y, Nakayama A, et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 2000;36:353–61. [PubMed]
61. Falini B, Stein H, Pileri S, et al. Expression of T-cell antigens on Hodgkin's and Sternberg-Reed cells of Hodgkin's disease. A combined immunocytochemical and immunohistological study using monoclonal antibodies. Histopathology 1987;12:1229–41.
62. Casey TT, Olson SJ, Cousar JB, et al. Immunophenotype of Reed-Sternberg cells: a study of 19 cases of Hodgkin's disease in plastic-embedded sections. Blood 1989;74:2624–8. [PubMed] 63. Müschen M, Rajewsky K, Bräuninger A, et al. Rare occurrence of classical Hodgkin's disease as a T-cell lymphoma. J Exp Med 2000;191:387–94. [PMC free article] [PubMed] 64. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084–92. [PubMed] 65. Gerdes J, Van Baarlen J, Pileri S, et al. Tumor cell growth fraction in Hodgkin's disease. Am J Pathol 1987;128:390–3. [PubMed] 66. Sabattini E, Gerdes J, Gherlinzoni F, et al. Comparison between the monoclonal antibodies Ki-67 and PC10 in 125 malignant lymphomas. J Pathol 1993;169:397–403. [PubMed]
67. Leoncini L, Close P, Bothur P, et al. Apoptosis in Hodgkin's disease: an in situ endlabelling study correlated with proliferation indices and expression of cell death gene, p53 and BCL-2. Curr Diagn Pathol 1995;2:51–2.
68. Leoncini L, Spina D, Close P, et al. Abortive mitosis and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's disease. Leuk Lymphoma 1996;22:119–24. [PubMed]
69. Spina D, Leoncini L, Close P, et al. Growth vs DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells. International Journal of Cancer 1996;66:179–83.
70. Leoncini L, Spina D, Close P, et al. Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virus. Leuk Lymphoma 1997;25:153–61. [PubMed] 71. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease: clinical impact of the immunophenotype. Am J Pathol 1997;151:1123–30. [PubMed] 72. Naresh KN, O'Conor GT, Soman CS, et al. A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin's disease at presentation and relapse. Hum Pathol 1997;28:549–55. [PubMed] 73. Smolewsky P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000;6:1150–60. [PubMed] 74. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998;16:471–3. [PubMed] 75. Bargou RC, Leng C, Krappmann D, et al. High level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340–7. [PubMed] 76. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999;94:3129–34. [PubMed] 77. Cabannes E, Khan G, Aillet F, et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for the IkappaBalpha. Oncogene 1999;18:3063–70. [PubMed] 78. Jugnickel B, Staratschek-Jox A, Braeuninger A, et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000;191:395–401. [PMC free article] [PubMed] 79. Krappmann D, Emmerich F, Kordes U, et al. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/ Reed-Sternberg cells. Oncogene 1999;18:943–53. [PubMed] 80. Montesinos-Rongen M, Roers A, Küppers R, et al. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 1999;94:1755–60. [PubMed] 81. Bullrich F, Morris SW, Hummel M, et al. Nucleophosmin (NPM) gene rearrangements in Ki-1 positive lymphomas. Cancer Res 1994;54:2873–7. [PubMed] 82. Orscheschek K, Merz H, Hell J, et al. Large-cell anaplastic lymphoma-specific translocation t(2;5)(p23;q35) in Hodgkin's disease: indication of a common pathogenesis? Lancet 1995;345:87–90. [PubMed] 83. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995;86:1954–60. [PubMed] 84. Weiss LM, Lopategui JR, Sun LH, et al. Absence of the t(2;5) in Hodgkin's disease. Blood 1995;85:2845–7. [PubMed] 85. Xerri L, Parc P, Hassoun J, et al. Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease. J Pathol 1996;178:128–32. [PubMed] 86. Nakamura S, Shiota M, Nakagawa A, et al. Anaplastic large cell lymphoma: a distinct molecular pathologic entity. A reappraisal with special reference to p80NPM/ALK expression. Am J Surg Pathol 1997;21:1420–32. [PubMed] 87. Pileri SA, Mason DY, Mori S, et al. Frequent expression of the p80 NPM–ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol 1997;150:1207–11. [PubMed]
88. Hutchinson RE, Banki K, Shuster JJ, et al. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 1997;8:37–42.
89. Pulford K, Lamant L, Morris S, et al. Detection of ALK and NPM-ALK protein in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394–404. [PubMed] 90. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol 1997;8:59–63. [PubMed]
91. Trümper L, Daus H, Merz H, et al. NPM/ALK fusion mRNA expression in Hodgkin and Reed-Sternberg cells is rare but does occur: results from single-cell cDNA analysis. Ann Oncol 1997;8:83–7.
92. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998;91:2076–84. [PubMed] 93. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of lymphomas (“ALK lymphomas”) with a wide morphologic spectrum. Am J Pathol 1998;153:875–86. [PubMed] 94. Poppema S, Kaleta J, Hepperle B, et al. Chromosomal abnormalities in patients with Hodgkin's disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells. J Natl Cancer Inst 1992;84:1789–93. [PubMed]
95. Vassallo J, Brousset P, Knecht H, et al. Detection of Epstein-Barr virus in Hodgkin's disease. Applied Immunohistochemistry 1993;1:213–19.
96. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743–51. [PubMed] 97. Leoncini L, Spina D, Nyong'o A, et al. Neoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy. Int J Cancer 1996;65:781–4. [PubMed] 98. Weinreb M, Day PJ, Niggli F, et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996;87:3828–36. [PubMed] 99. Brousset P, Schlaifer D, Meggetto F, et al. Persistence of the same viral strain in early and late relapses of Epstein-Barr virus-associated Hodgkin's disease. Blood 1994;84:2447–51. [PubMed] 100. Lennert K, Mohri N. Histologische klassifizierung und vorkommen des M. Hodgkin. Internist (Berl) 1974;15:57–65. [PubMed] 101. Diebold J, Audouin J. Maladie de Hodgkin. Une ou plusieurs maladies. Ann Pathol 1989;9:84–91. [PubMed] 102. MacLennan KA, Bennett MH, Tu A, et al. Relationship of histologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989;64:1686–93. [PubMed]
103. Grogan TM. Hodgkin's disease. In: Jaffe ES, ed. Surgical pathology of the lymph nodes and related organs. Philadelphia: Saunders, 1995:133–92.
104. Banks PM. The distinction of Hodgkin's disease from T-cell lymphoma. Semin Diagn Pathol 1992;9:279–83. [PubMed]
105. Diebold J, Jungman P, Molina T, et al. Recent advances in Hodgkin's disease: an overview and review of the literature. Curr Diagn Pathol 1995;2:153–62.
106. Alavaikko MJ, Blanco G, Aine R, et al. Follicular dendritic cells have prognostic relevance in Hodgkin's disease. Am J Clin Pathol 1994;101:761–7. [PubMed] 107. Baur AS, Mengi-Moraw C, Michel G, et al. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998;32:512–20. [PubMed] 108. Strickler JG, Michie SA, Warnke RA, et al. The “syncytial variant” of nodular sclerosing Hodgkin's disease. Am J Surg Pathol 1986;10:470–7. [PubMed] 109. Ben-Yehuda-Salz D, Ben-Yehuda A, Polliack A, et al. Syncytial variant of nodular sclerosing Hodgkin's disease. A new clinicopathologic entity. Cancer 1990;65:1167–72. [PubMed] 110. Bennett MH, MacLennan KA, Easterling MG, et al. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report No 22). Clin Radiol 1983;34:497–501. [PubMed] 111. Ferry JA, Linggod RM, Convery KM, et al. Hodgkin's disease, nodular sclerosing type: implications of histologic subclassification. Cancer 1993;71:457–63. [PubMed] 112. D'Amore ESG, Lee CKK, Appli DM, et al. Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type: a study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. Arch Pathol Lab Med 1992;116:856–61. [PubMed] 113. Hess JL, Bodis S, Pinkus G, et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994;74:708–14. [PubMed] 114. Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology 1990;16:383–91. [PubMed] 115. Pileri S, Bocchia M, Baroni CD, et al. Anaplastic large cell lymphoma (CD30+/Ki-1+): results of the prospective clinico-pathologic study of 69 cases. Br J Haematol 1994;86:513–23. [PubMed]
116. Pileri S. Controversies on Hodgkin's disease and anaplastic large cell lymphoma. Hematopathology study group of the societa Italiana di anatomia patologica. Haematologia 1994;79:299–310.
117. Pileri SA, Piccaluga A, Poggi S, et al. Anaplastic large cell lymphoma: update of findings. Leuk Lymphoma 1995;18:17–25. [PubMed]
118. Pileri SA, Poggi S, Sabattini E, et al. Anaplastic large cell lymphoma Hodgkin's like. Current Diagnostic Pathology 1995;2:57–8.
119. The non-Hodgkin's lymphoma classification project: a clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909–18. [PubMed] 120. Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistochemical findings of 18 patients treated with two different third generation regimens. Br J Haematol 1995;89:780–9. [PubMed] 121. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicentric study of 106 patients. J Clin Oncol 1997;15:1646–53. [PubMed] 122. Aisenberg AC. Primary large cell lymphoma of the mediatinum. Semin Oncol 1999;26:251–8. [PubMed] 123. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999;112:241–7. [PubMed] 124. Chadburn A, Frizzera G. Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma. Am J Clin Pathol 1999;112:155–8. [PubMed] 125. Copie Bergman C, Gaulard P, Maouche CL, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood 1999;94:3567–75. [PubMed] 126. Bacchi CE, Dorfman RF, Hoppe RT, et al. Metastatic carcinoma in lymph nodes simulating syncytial variant of nodular sclerosing Hodgkin's disease. Am J Clin Pathol 1991;96:589–93. [PubMed] 127. Zarate-Osorno A, Jaffe ES, Medeiros LJ. Metastatic nasopharyngeal carcinoma initially presenting as cervical lymphadenopathy: a report of two cases that resembled Hodgkin's disease. Arch Pathol Lab Med 1992;116:862–5. [PubMed] 128. Doggett RS, Colby TV, Dorfman RF. Interfollicular Hodgkin's disease. Am J Surg Pathol 1983;7:145–9. [PubMed] 129. Maheswaran PR, Ramsay AD, Norton AJ, et al. Hodgkin's disease presenting with the histological features of Castleman's disease. Histopathology 1991;18:249–53. [PubMed] 130. Hsu S-M, Xie S-S, Hsu P-L, et al. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic feature of Castleman's disease. Am J Pathol 1992;141:129–38. [PubMed] 131. Lukes RJ. Criteria for involvement of lymph node, bone marrow, spleen and liver in Hodgkin's disease. Cancer Res 1971;31:1755–67. [PubMed] 132. Patsouris E, Noel H, Lennert K. Cytohistologic and immunohistochemical findings in Hodgkin's disease, mixed cellularity type with a high content of epithelioid cells. Am J Surg Pathol 1989;13:1014–22. [PubMed] 133. Butler JJ. The histologic diagnosis of Hodgkin's disease. Semin Diagn Pathol 1992;9:252–6. [PubMed] 134. Hastrup N, Ralfkiaer E, Pallesen G. Aberrant phenotypes in peripheral T-cell lymphomas. J Clin Pathol 1989;42:398–402. [PMC free article] [PubMed] 135. Pileri SA, Ascani S, Sabattini E, et al. Peripheral T-cell lymphoma: a developing concept. Ann Oncol 1998;9:797–801. [PubMed] 136. Osborne BM, Uthman MO, Butler JJ, et al. Differentiation of T-cell lymphoma from Hodgkin's disease: mitotic rate and S-phase analysis. Am J Clin Pathol 1990;93:227–32. [PubMed]
137. Jaffe ES, Longo DL, Cossman J, et al. Diffuse B cell lymphomas with T cell predominance in patients with follicular lymphoma or “pseudo T cell lymphoma”. Lab Invest 1984;50:2A–8A.
138. McBride JA, Rodriguez J, Luthra R, et al. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol 1996;20:193–201. [PubMed] 139. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988;12:433–43. [PubMed]
140. De Wolf-Peeters C, Pittaluga S. T-cell rich B-cell lymphoma: a morphological variety of non-Hodgkin's lymphomas or a clinicopathological entity? Histopathology 1995;28:381–3.
141. Nguyen DT, Diamond LW, Hansmann M-L, et al. Differential diagnosis of L26-positive, CD15-negative Hodgkin's disease and large B-cell lymphoma with a high content of reactive T-cells: a morphologic and immunohistochemical study. Hematopathology and Molecular Hematology 1996;10:135–50. [PubMed] 142. De Jong D, Van Gorp J, Sie-Go D, et al. T-cell-rich B-cell non Hodgkin's lymphoma: a progressed form of follicle center cell lymphoma and lymphocyte predominance Hodgkin's disease. Histopathology 1996;28:15–24. [PubMed] 143. Skinnider BF, Connors JM, Gascoyne RD. Bone marrow involvement in T-cell-rich B-cell lymphoma. Am J Clin Pathol 1997;108:570–8. [PubMed]
144. Fleming MD, Shahrafei A, Dorfman D. Absence of dendritic reticulum cell staining is helpful for distinguishing T-cell-rich B-cell lymphoma from lymphocyte predominance Hodgkin's disease. Applied Immunohistochemistry 1998;6:16–22.
145. Kinney MC, Greer JP, Stein RS, et al. Lymphocyte depletion Hodgkin's disease: histopathologic diagnosis of marrow involvement. Am J Surg Pathol 1986;10:219–26. [PubMed] 146. Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma, a morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988;12:264–74. [PubMed] 147. Pelstring R, Zellmer R, Sulak L, et al. Hodgkin's disease in association with human immunodeficiency virus infection. Cancer 1991;67:1865–73. [PubMed] 148. Greer JP, Kinney MC, Collins RD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 1991;9:539–47. [PubMed] 149. Kant JA, Hubbard SM, Longo DL, et al. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. J Clin Oncol 1986;4:284–94. [PubMed] 150. Suster S, Moran CA. Pleomorphic large cell lymphomas of the mediastinum. Am J Surg Pathol 1996;20:224–32. [PubMed]
151. Pileri SA, Sabattini E, Falini B. Critical commentary to “Inflammatory fibrosarcoma: another imitator of Hodgkin's disease ?” Letter to the case. Pathol Res Pract 1996;192:481–2.
152. Mirra M, Falconieri G, Zanconati F, et al. Inflammatory fibrosarcoma: another imitator of Hodgkin's disease? Pathol Res Pract 1996;192:474–8. [PubMed] 153. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978;41:2250–66. [PubMed] 154. Argani P, Facchetti F, Inghirami G, et al. Lymphocyte-rich well-differentiated liposarcoma: report of nine cases. Am J Surg Pathol 1997;21:884–95. [PubMed] 155. Hansmann M-L, Wacker H-H, Radzum HJ. Paragranuloma is a variant of Hodgkin's disease with predominance of B-cells. Virchows Arch A Pathol Anat Histopathol 1986;409:171–81. [PubMed]
156. Hansmann M-L, Fellbaum C, Hui PK, et al. Correlation of content of B cells and Leu7-positive cells with subtype and stage in lymphocyte predominance type Hodgkin's disease. J Cancer Res Clin Oncol 1988;119:405–10.
157. Ashton-Key M, Thorpe PA, Allen JP, et al. Follicular Hodgkin's disease. Am J Surg Pathol 1995;19:1294–9. [PubMed]
158. Diehl V, Stein H, Sextro M, et al. Lymphocyte predominance Hodgkin's disease: a European task force on lymphoma project [abstract]. Blood 1996;88(suppl 1):294a.
159. Dolginow D, Colby TV. Recurrent Hodgkin's disease in treated sites. Cancer 1981;48:1124–6. [PubMed] 160. Serraino D, Pezzotti P, Dorrucci M, et al. Cancer incidence in a cohort of human immunodeficiency virus seroconverters. HIV Italian seroconversion study group. Cancer 1997;79:1004–8. [PubMed] 161. Goedert JJ, Coté TR, Virgo P, et al. for the AIDS-cancer match study group: spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833–9. [PubMed] 162. Serrano M, Bellas C, Campo E, et al. Hodgkin's disease in patients with antibodies to human immunodeficiency virus. Cancer 1990;65:2248–54. [PubMed] 163. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol 1995;13:1758–67. [PubMed] 164. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999;93:2319–26. [PubMed] 165. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection. Comparison with ordinary Hodgkin's disease. Am J Surg Pathol 1996;20:1520–4. [PubMed] 166. Wang D, Leibowitz D, Kieff E, et al. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831–40. [PubMed] 167. Baichwal VR, Sugden B. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988;2:461–7. [PubMed]
168. IARC Monographs on the evaluation of carcinogenic risks to humans, Vol. 67. Human immunodeficiency viruses and human T-cell lymphotropic viruses. Lyon, France: International Agency for Research on Cancer Health Organisation, 1996.
169. Hansmann ML, Stein H, Fellbaum C, et al. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol 1989;20:1169–75. [PubMed]
170. Jaffe ES, Zarate-Osorno A, Kingma DW, et al. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas. Ann Oncol 1994;5:S7–11.
171. Kim H. Composite lymphoma and related disorders. Am J Clin Pathol 1993;99:445–51. [PubMed] 172. Wickert RS, Weisenburger DD, Tierens A, et al. Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large B-cell lymphoma of B cell lineage. Blood 1995;86:2312–20. [PubMed] 173. Grainer TC, Gascoyne RD, Anderson ME, et al. Nodular lymphocyte-predominant Hodgkin's disease associated with large cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 1996;88:657–66. [PubMed] 174. Pan LX, Diss TC, Peng HZ, et al. Nodular lymphocyte predominance Hodgkin's disease: a monoclonal or polyclonal B-cell disorder? Blood 1996;87:2428–34. [PubMed] 175. Yoshinaga H, Ohashi K, Yamamoto K, et al. Clonal identification of Burkitt's lymphoma arising from lymphocyte-predominant Hodgkin's disease. Br J Haematol 1996;95:380–2. [PubMed]
176. Kadin M. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin's disease. Lancet 1985;ii:864–5.
177. Casey TT, Cousar JB, Maugum M, et al. Monomorphic lymphomas arising in patients with Hodgkin's disease. Correlation of morphologic, immunophenotypic, and molecular genetic findings in 12 cases. Am J Pathol 1990;136:81–94. [PubMed] 178. Brecher M, Banks PM. Hodgkin's disease variant of Richter's syndrome. Report of eight cases. Am J Clin Pathol 1990;93:333–9. [PubMed] 179. Gonzalez CL, Medeiros LJ, Jaffe ES. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. Am J Clin Pathol 1991;96:81–9. [PubMed] 180. Williams J, Schned A, Cotelingam JD, et al. Chronic lymphocytic leukemia with coexistent Hodgkin's disease. Implications for the origin of the Reed-Sternberg cell. Am J Surg Pathol 1991;15:33–42. [PubMed] 181. Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992;326:1115–22. [PubMed] 182. Jaffe ES, Zorate-Osorno A, Medeiros LF, et al. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphoma—lessons learned from composite and sequential malignancies. Semin Diagn Pathol 1992;9:297–303. [PubMed] 183. Harris NL. The relationship between Hodgkin's disease and non-Hodgkin's lymphoma. Semin Diagn Pathol 1992;9:304–10. [PubMed] 184. Zarate-Osorno A, Medeiros J, Kingma DW, et al. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol 1993;17:123–32. [PubMed] 185. Le Brun DP, Ngan BY, Weiss LM, et al. The bcl-2 oncogene in Hodgkin's disease arising in the setting of follicular non-Hodgkin lymphoma. Blood 1994;83:223–30. [PubMed] 186. Brousset P, Lamant L, Viraben R, et al. Hodgkin's disease following mycosis fungoides: phenotypic and molecular evidence for different tumour cell clones. J Clin Pathol 1996;49:504–7. [PMC free article] [PubMed] 187. Ohno T, Trenn G, Wu G, et al. The clonal relationship between nodular sclerosis Hodgkin's disease with clonal Reed-Sternberg cell population and a subsequent B-cell small noncleaved lymphoma. Mod Pathol 1998;11:485–90. [PubMed] 188. Ohno T, Smir BN, Weisenburger DD, et al. Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with Hodgkin's transformation. Blood 1998;91:1757–61. [PubMed]
189. Jaffe ES, Muller-Hermelink HK. Relationship between Hodgkin's disease and non-Hodgkin's lymphomas. In: Mauch PM, Armitage JO, Diehl V, et al, eds. Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins, 1999:181–93.
190. Bräuninger A, Hansmann M-L, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999;340:1239–47. [PubMed] 191. Marafioti T, Hummel M, Anagnostopoulos I, et al. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 1999;17:3804–9. [PubMed]
192. Bellan C, Lazzi S, Zassi M, et al. Immunoglobulin gene rearrangement analysis in Hodgkin's disease associated with large B-cell lymphoma in the same patient: evidence for receptor revision of immunoglobulin heavy chain variable genes in Hodgkin-Reed-Sternberg cells? Diagn Mol Pathol [In press.]
193. Torlakovic E, Tierens A, Dang HD, et al. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001;159:1807–14. [PubMed]